Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.505
-0.215 (-4.56%)
May 15, 2026, 10:48 AM EDT - Market open
Nuvation Bio Revenue
Nuvation Bio had revenue of $83.23M in the quarter ending March 31, 2026, with 2,598.70% growth. This brings the company's revenue in the last twelve months to $143.05M, up 1,205.52% year-over-year. In the year 2025, Nuvation Bio had annual revenue of $62.90M with 698.96% growth.
Revenue (ttm)
$143.05M
Revenue Growth
+1,205.52%
P/S Ratio
11.49
Revenue / Employee
$465,948
Employees
307
Market Cap
1.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.90M | 55.03M | 698.96% |
| Dec 31, 2024 | 7.87M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 899.11M |
| Ardelyx | 427.68M |
| Innoviva | 420.69M |
| Vericel | 292.09M |
| Zymeworks | 81.26M |
| Nurix Therapeutics | 71.78M |
| Viridian Therapeutics | 70.92M |
| Recursion Pharmaceuticals | 66.41M |
NUVB News
- 1 day ago - Nuvation Bio collaborating with Thermo Fisher to manufacture Ibtrozi in NSCLC - TheFly
- 1 day ago - Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer - PRNewsWire
- 1 day ago - Nuvation Bio Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 8 days ago - Nuvation Bio: FDA accepts sNDA with updated data for IBTROZI - TheFly
- 9 days ago - Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer - PRNewsWire
- 9 days ago - Nuvation Bio to Participate in Upcoming Investor Conferences - PRNewsWire
- 10 days ago - Nuvation Bio Earnings Call Transcript: Q1 2026 - Transcripts
- 10 days ago - Nuvation Bio reports Q1 EPS 1c, consensus 5c - TheFly